These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23847109)

  • 21. Treatment of hyperammonemia in liver failure.
    Jover-Cobos M; Khetan V; Jalan R
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis.
    Vierling JM; Mokhtarani M; Brown RS; Mantry P; Rockey DC; Ghabril M; Rowell R; Jurek M; Coakley DF; Scharschmidt BF
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):903-906.e1. PubMed ID: 26707685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
    Blanco Vela CI; Poo Ramírez JL
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
    Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M
    Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy for hyperammonemia.
    Hadjihambi A; Khetan V; Jalan R
    Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts.
    van Straten G; van Dalen D; Mesu SJ; Rothuizen J; Teske E; Spee B; Favier RP; van Geijlswijk IM
    J Vet Intern Med; 2019 May; 33(3):1331-1335. PubMed ID: 30916412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.
    Holecek M
    Metab Brain Dis; 2014 Mar; 29(1):9-17. PubMed ID: 23996300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
    Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
    Rahimi RS; Safadi R; Thabut D; Bhamidimarri KR; Pyrsopoulos N; Potthoff A; Bukofzer S; Bajaj JS
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2626-2635.e7. PubMed ID: 33069881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamine and hyperammonemic crises in patients with urea cycle disorders.
    Lee B; Diaz GA; Rhead W; Lichter-Konecki U; Feigenbaum A; Berry SA; Le Mons C; Bartley J; Longo N; Nagamani SC; Berquist W; Gallagher RC; Harding CO; McCandless SE; Smith W; Schulze A; Marino M; Rowell R; Coakley DF; Mokhtarani M; Scharschmidt BF
    Mol Genet Metab; 2016 Jan; 117(1):27-32. PubMed ID: 26586473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitation of phenylbutyrate metabolites by UPLC-MS/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels.
    Jiang Y; Almannai M; Sutton VR; Sun Q; Elsea SH
    Mol Genet Metab; 2017 Nov; 122(3):39-45. PubMed ID: 28888854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial.
    Katayama K; Saito M; Kawaguchi T; Endo R; Sawara K; Nishiguchi S; Kato A; Kohgo H; Suzuki K; Sakaida I; Ueno Y; Habu D; Ito T; Moriwaki H; Suzuki K
    Nutrition; 2014; 30(11-12):1409-14. PubMed ID: 25280421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
    Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
    Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.